Long-Term Results of Drug Treatment for Crohn’s Disease Strictures
Clinical Gastroenterology and Hepatology · 2026-11 · 24 (11) · 3137-3144
DOI: 10.1016/j.cgh.2025.09.014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-11. Verfasst von Grace C Lovett und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, St. Vincent's Hospital Melbourne, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, A…. Hauptthemen laut MEDLINE: Crohn Disease, Adalimumab, Anti-Inflammatory Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: AbbVie Inc, National Health and Medical Research Council, Crohn's and Colitis Foundation of America.
Abstract (Originalsprache)
BACKGROUND & AIMS: Recent controlled data from the STRIDENT study suggest that, in the short-term, drug treatment effectively relieves symptoms and improves bowel wall morphology. Here, we present the long-term results of this clinical trial, identifying predictors of treatment outcomes. METHODS: Patients with symptomatic Crohn's disease strictures were randomized 2:1 to high-dose adalimumab induction followed by 40 mg fortnightly plus thiopurine, with dose increase at 4 and/or 8 months if evidence of persisting inflammation, or standard dose adalimumab monotherapy. Baseline stricture magnetic resonance imaging risk score was assessed: prestenotic dilation ≥30 mm, stricture length >50 mm, and bowel wall thickness ≥10 mm (each factor assigned a score of 1). Patients were assessed at 12 months for clinical response (reduction in the 14-day obstructive symptom score). Follow-up interviews were performed at a minimum of 4 years. RESULTS: In the initial 12-month study, 52 patients were randomized to the intensive and 25 to the standard treatment arm, with 64 of 77 (83%) completing at least 12 months of therapy, whereas 13 patients (17%) withdrew: 8 for surgical treatment and 5 for other reasons. Following study completion at 12 months, 12 of 77 patients (16%) required endoscopic dilation, and 22 of 77 patients (29%) required surgery. Clinical responders had a lower rate of surgical resection compared with nonresponders (20% vs 52%; P < .001). The stricture magnetic resonance imaging risk score predicted surgery-free survival (odds ratio, 2.34; 95% confidence interval, 1.32-4.16; P = .004). CONCLUSIONS: The clinical response to adalimumab is durable in a majority of patients beyond 4 years of therapy. In patients with symptomatic Crohn's disease strictures, drug treatment is a viable initial treatment. Stricture Definition and Treatment (STRIDENT) Drug Therapy Study: Clinicaltrials.gov, Number: NCT03220841.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, St. Vincent's Hospital Melbourne, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.
- Department of Medicine, University of Melbourne, Melbourne, Australia; Department of Radiology, St Vincent's Hospital Melbourne, Melbourne, Australia.
- Department of Gastroenterology, St. Vincent's Hospital Melbourne, Melbourne, Australia.
- Department of Gastroenterology, St. Vincent's Hospital Melbourne, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia. Electronic address: mkamm@unimelb.edu.au.
Förderung
- AbbVie Inc
- National Health and Medical Research Council
- Crohn's and Colitis Foundation of America
Zitieren
APA
Lovett, G. C., Schulberg, J. D., Hamilton, A. L., Wright, E. K., Holt, B. A., Sutherland, T. R., Ross, A. L., & Kamm, M. A. (2026). Long-Term Results of Drug Treatment for Crohn’s Disease Strictures. Clinical Gastroenterology and Hepatology, 24(11), 3137-3144. https://doi.org/10.1016/j.cgh.2025.09.014
Vancouver
Lovett GC, Schulberg JD, Hamilton AL, Wright EK, Holt BA, Sutherland TR, et al. Long-Term Results of Drug Treatment for Crohn’s Disease Strictures. Clinical Gastroenterology and Hepatology. 2026;24(11):3137-3144. doi:10.1016/j.cgh.2025.09.014
BibTeX
@article{Lovett2026,
author = {Lovett, Grace C and Schulberg, Julien D and Hamilton, Amy L and Wright, Emily K and Holt, Bronte A and Sutherland, Tom R and Ross, Alyson L and Kamm, Michael A},
title = {Long-Term Results of Drug Treatment for Crohn’s Disease Strictures},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {11},
pages = {3137--3144},
doi = {10.1016/j.cgh.2025.09.014}
}
EUVIMED